The Study of Fibroblast Growth Factor-23 in Renal Failure Patients Undergoing Dialysis with or without Corona Vaccine

Abstract Background: In the past 10 years, FGF23 has emerged as a potential symptomatic, prognostic biomarker, and restorative objective in several circumstances. Vaccination is one of the best techniques to stop the pandemic. However, following COVID-19 vaccination, both new and recurrent renal disorders have been reported. In the current study, levels of FGF23 were explored in renal patients with and without the corona vaccine. Other inflammatory markers also correlated with these levels. Objectives: The goal of the current investigation was to estimate FGF23 levels in renal failure patients undergoing dialysis with or without corona vaccination, as well as the relationship between these levels and other frequently used biomarkers. Materials and Methods: Blood tests were gathered from 60 patients with renal disappointment disease with and without vaccination with age ranging from 30 to 65 years and 30 age-matched healthy controls were included the study. We examined how other parameters and serum FGF23 levels were related. Results: This study found a substantial link between FGF23 and these parameters in patients who received the corona virus vaccine and other biomarkers, and there was an inverse correlation FGF23 between patients who did not receive the corona virus vaccine and some other parameters. Patients with renal failure undergoing dialysis also had elevated levels of FGF23. FGF23 levels are higher in patients with kidney issues than in healthy individual, even if they have received the COVID-19 vaccine. Conclusion: FGF23 is a promising marker for tracking disease progression. However, FGF23 levels in patients who received vaccination did not differ significantly from those who did not.